SCHEMBL688516

SCHEMBL688516

CCCCCCCCCCCC(CCCCCCCC)CC(C)(C)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.47
ACACA Q13085 1/20 0.47
GPR84 Q9NQS5 7/20 0.47
FFAR1 O14842 2/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.46
LCK P06239 1/20 0.46
PPARD Q03181 1/20 0.46
ZDHHC20 Q5W0Z9 1/20 0.46
ZDHHC2 Q9UIJ5 1/20 0.46
CA2 P00918 1/20 0.44
HSPD1 P10809 1/20 0.44
BLM P54132 1/20 0.44
HSPE1 P61604 1/20 0.44
GRIK1 P39086 1/20 0.43
GRIK2 Q13002 1/20 0.43
FFAR4 Q5NUL3 1/20 0.43
ACE2 Q9BYF1 1/20 0.43
FDPS P14324 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18595199 1.00 ACACB (0.47) ACACBACACAGPR84FFAR1LMNA
SCHEMBL27559167 0.96 ACACB (0.44) ACACBACACAGPR84FFAR1LMNA
SCHEMBL27493101 0.88 GRIK1 (0.41) ACACBACACAGPR84FFAR1LMNA
SCHEMBL27578236 0.85 ACE2 (0.42) ACACBACACAGPR84FFAR1LMNA
SCHEMBL1116222 0.85 CA2 (0.48) ACACBACACACA2
SCHEMBL3901635 0.83 ACACB (0.55) ACACBACACAGPR84FFAR1LMNA
SCHEMBL28728386 0.83 ACACB (0.59) ACACBACACAGPR84FFAR1MAPT
SCHEMBL3742437 0.83 CA2 (0.47) GPR84FFAR1LMNAMAPTLCK
SCHEMBL1018592 0.83 CA2 (0.47) GPR84FFAR1LMNAMAPTLCK
SCHEMBL22181671 0.83 ACE2 (0.55) ACACBACACAGPR84FFAR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070122508-A1 Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease HELIXIR CO., LTD. (KR) 2007-05-31 US claimed
US-12616730-B2 Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof MEDIHELPLINE CO., LTD (KR) 2026-05-05 US disclosed
US-20230127213-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE TREATMENT OR ALLEVIATION OF SKIN ULCER AND THE USE THEREOF PARK, OK NAM (KR) 2023-04-27 US disclosed
US-20230103514-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE SKIN REGENERATION AND THE TREATMENT OR ALLEVIATION OF SKIN WOUND AND THE USE THEREOF MEDIHELPLINE CO., LTD (KR) 2023-04-06 US disclosed
US-20230100173-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR TLSP INHIBITION AND THE TREATMENT OR ALLEVIATION OF SKIN INFLAMMATORY DISEASE AND THE USE THEREOF MEDIHELPLINE CO., LTD (KR) 2023-03-30 US disclosed
EP-4117700-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR TLSP INHIBITION AND THE TREATMENT OR ALLEVIATION OF SKIN INFLAMMATORY DISEASE AND THE USE THEREOF Medihelpline Co., Ltd. (KR) 2023-01-18 EP disclosed
EP-4117698-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE SKIN REGENERATION AND THE TREATMENT OR ALLEVIATION OF SKIN WOUND AND THE USE THEREOF Medihelpline Co., Ltd. (KR) 2023-01-18 EP disclosed
EP-4117699-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE TREATMENT OR ALLEVIATION OF SKIN ULCER AND THE USE THEREOF Medihelpline Co., Ltd. (KR) 2023-01-18 EP disclosed
CN-115297879-A Topical composition comprising arillus longan combined crude drug extract for regenerating skin and treating or improving skin wound, and its application (株)美迪合伙来音 2022-11-04 CN disclosed
CN-115279387-A Topical composition comprising arillus longan combined crude drug extract for inhibiting TSLP and treating or improving skin inflammation diseases, and its application (株)美迪合伙来音 2022-11-01 CN disclosed
US-20070122508-A1 Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease HELIXIR CO., LTD. (KR) 2007-05-31 US disclosed
WO-2007046636-A1 HERBAL COMPOSITION FOR PREVENTING AND IMPROVING BALDNESS KMSI CO., LTD (KR) 2007-04-26 WO disclosed
WO-2007004832-A1 COMPOSITION COMPRISING AN EXTRACT OF CRINUM ASIATICUM LINNE HAVING ANTI-ALLERGIC AND ANTI-INFLAMMATORY ACTIVITY BIOLAND LTD. (KR) 2007-01-11 WO disclosed
WO-2006093793-A2 COMPOSITIONS COMPRISING ACTINIDIA AND METHODS OF USE THEREOF EFFICAS, INC. (US) 2006-09-08 WO disclosed
WO-2006090939-A1 COSMETIC COMPOSITION COMPRISING BETA-FRUCTOSYL-L-ASCORBIC ACID FOR SKIN WHITENING BIOLAND LTD. (KR) 2006-08-31 WO disclosed
WO-2006016728-A1 COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA FOR PREVENTING AND TREATING BALDNESS DISORDERS AND SEBORRHEIC SKIN DISORDERS HELIXIR CO., LTD. (KR) 2006-02-16 WO disclosed
EP-1551433-A1 COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA AND RELATED SPECIES FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE AND NON-ALLERGIC INFLAMMATORY DISEASE Pangenomics Co., Ltd. (KR) 2005-07-13 EP disclosed
WO-2004096171-A1 SKIN WHITENING COSMETIC COMPOSITION COMPRISING THE EXTRACT OF MACHILUS THUNBERGII AND THE COMPOUNDS ISOLATED THEREFROM YEUNGNAM EDUCATIONAL FOUNDATION (KR) 2004-11-11 WO disclosed
WO-2004017982-A1 COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA AND RELATED SPECIES FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE AND NON-ALLERGIC INFLAMMATORY DISEASE PANGENOMICS CO., LTD (KR) 2004-03-04 WO disclosed
US-20040037909-A1 Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease VIROMED CO., LTD. (KR) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12616730-B2 Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof CUTA, VEGFA, MMP8 ACACB 2123/4885ACACA 982/4885GPR84 3533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.